Brief: AIM Vaccine Logs H1 Capex RMB 102.5 Mln
27/08/2025 15:44
Aug 27 (Reuters) - AIM Vaccine Co Ltd 6660.HK: H1 CAPEX RMB 102.5 MILLION H1 REVENUE RMB 514.7 MILLION H1 GROSS MARGIN 66.3% H1 GROSS PROFIT RMB 341.2 MILLION HY LOSS ATTRIBUTABLE RMB131.1 MILLION Further company coverage: 6660.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on AIM Vaccine
See all newsBrief: AIM Vaccine Co Submits Application For Human Diploid Cell Rabies Vaccine In China
Brief: AIM Vaccine Says Tibet Bohai To Subscribe 37.4 Million Shares At RMB1.07 Each
Brief: AIM Vaccine Approves Issuance Of Up To 40 Million Domestic Shares
Brief: Aim Vaccine Says Serum-Free Rabies Vaccine Passes Inspection
Brief: AIM Vaccine Updates On 20-Valent Pneumococcal Polysaccharide Conjugate Vaccine